HALOZYME THERAPEUTICS / RIESENPOTENTIAL ? - 500 Beiträge pro Seite

[cyberhai]

Haben bereits mit Cumulase einen Stoff in der Vermarktung, der bei der künstlichen Befruchtung die Erfolgsquote um ca. 10 % steigert. Hier die Pipeline:



Chart:



Zu Cumulase:

Cumulase™ is an ex vivo (used outside of the body) formulation of rHuPH20 to replace the bovine enzyme currently used for the preparation of oocytes (eggs) prior to in vitro fertilization (IVF) during the process of intracytoplasmic sperm injection (ICSI), in which
the enzyme is an essential component. The enzyme strips away the hyaluronic acid that surrounds the oocyte. This allows the clinician to then perform the ICSI procedure, injecting the sperm into the oocyte. The FDA considers hyaluronidase IVF products to be medical devices subject to 510(k) clearance, providing a unique opportunity to potentially bring rHuPH20 technology to market as early as fourth quarter 2004.

Infertile couples are increasingly turning to IVF as a viable option for family planning, thus creating more demand, usage, and awareness. Nearly 100,000 IVF cycles were completed in 2000 in the U.S., growing at 11% annually. Approximately 400,000 IVF cycles were completed in 2000 outside the U.S., also growing at 11% annually. Nearly 760,000 total IVF cycles worldwide are estimated in 2004. The total Cumulase market consists of an estimated 500,000 ICSI procedures worldwide in 2004 (Source: CDC, 2001; ESHRE, 2002).

Zu Enhanze:

Enhanze™ Technology, Halozyme`s proprietary drug enhancement system, is being developed to facilitate rapid delivery of other drugs by safely and temporarily degrading hyaluronic acid.

Hylenex™, the first product in Halozyme`s Enhanze™ Technology portfolio, is being developed to facilitate subcutaneous diffusion of anesthesia in ophthalmic surgery, as well as other diverse indications. Hylenex™ is expected to be the first and only synthetic alternative to the slaughterhouse-derived hyaluronidase enzyme currently in use for drug enhancement. Recombinant human hyaluronidase has more than 100 times higher purity than the active ingredient in Wydase®, Wyeth`s discontinued bovine enzyme previously used for anesthesia diffusion enhancement.

A natural extension of Hylenex would be applying this technology, used as a spreading factor for local anesthetics around the eye, to other areas of the body. For example, lidocaine and bupivacaine are administered for most minor surgical operations requiring local anesthesia. Hylenex may also facilitate the penetration and dispersion of other drugs by temporarily opening flow channels under the skin. Molecules as large as 200 nanometers may pass freely through the perforated extracellular matrix, which recovers its normal density within 24 hours, leading to a drug delivery platform which does not permanently alter the architecture of the skin.

The most significant market for Hylenex is in ophthalmology, consisting of approximately 6.4 million local anesthesia procedures (or 45% of the 14.2 million total estimated cataract surgery procedures) worldwide in 2004 (Source: Medtech Insight, 2002; Marketscope, 2001; Review of Ophthalmology, 2003). Halozyme filed an NDA for Hylenex in the first quarter of 2005.

Aktuelle MK: 94,93 Mio. Dollar lt. Yahoo

Ich sehe hier langfristig einiges Potential, der Wert ist noch nicht entdeckt, sobald hier ein Börsenmagazin darauf hinweist, werden wir den Ausbruch haben.

Die Börsenumsätze sind derzeit noch minimal.

Eure Meinungen ?

Gruß Cyberhai

[cyberhai]

Rodman & Renshaw, LLC Announces Investment Opinion on Halozyme Therapeutics, Inc.
Tuesday September 13, 4:53 pm ET
Rodman & Renshaw, LLC Initiates Coverage of Halozyme Therapeutics, Inc. With A Market Outperform Rating; Analyst Sets 12 Month Target Price of $2.88

NEW YORK--(BUSINESS WIRE)--Sept. 13, 2005-- Rodman & Renshaw, LLC initiated research coverage of Halozyme Therapeutics, Inc. (Amex: HTI - News) with a Market Outperform Rating and a 12-month price target $2.88. Matthew N. Murray, Senior Biotechnology Analyst, issued the report.

ADVERTISEMENT
click here
About Rodman & Renshaw, LLC

Rodman & Renshaw is a privately held, full-service investment bank committed to fostering the long-term success of growth companies through capital raising, strategic advice, insightful research, and the development of institutional support. More information is available at www.rodmanandrenshaw.com

None of the research analysts or the research analyst`s household has a financial interest in the securities of Halozyme Therapeutics, Inc. (including, without limitation, any option, right, warrant, future, long or short position).

As of August 31, 2005, neither Rodman & Renshaw, LLC nor its affiliates beneficially own 1% or more of any class of common equity securities of Halozyme Therapeutics, Inc.

Neither the research analyst nor Rodman & Renshaw, LLC has any material conflict of interest with Halozyme Therapeutics, Inc., of which the research analyst knows or has reason to know at the time of publication of this research report.

Rodman & Renshaw, LLC or its affiliates did not receive compensation from Halozyme Therapeutics, Inc. for investment banking services within the last twelve months and Rodman & Renshaw, LLC intends to seek compensation from Halozyme Therapeutics, Inc. for investment banking services within three months, following publication of the research report.

Neither the research analyst nor any member of the research analyst`s household nor Rodman & Renshaw, LLC serves as an officer, director or advisory board member of Halozyme Therapeutics, Inc.

Rodman & Renshaw, LLC makes a market in Halozyme Therapeutics, Inc.`s securities as of the date of this research report.

The above information is not intended to be used as a primary basis of investment decisions. It is not a representation by Rodman & Renshaw, LLC or an offer or the solicitation of an offer to buy any security. Before investing in Halozyme Therapeutics, Inc., you should carefully consider your risk tolerance and financial objectives.

[cyberhai]

AP
Halozyme, Baxter Get FDA OK on Hylenex
Monday December 5, 1:32 pm ET
Halozyme Therapeutics, Baxter International Say FDA Approves Drug Delivery Product Hylenex

SAN DIEGO (AP) -- Halozyme Therapeutics Inc. and Baxter International Inc. said Monday that the Food and Drug Administration approved the drug delivery product Hylenex.

The approval is the first for Halozyme. Partner Baxter Healthcare Corp., a unit of Baxter, will market and sell the product in the United States.

Hylenex is an injected product that uses a human enzyme to improve the dispersion and absorption of other injected drugs, an alternative to animal-derived products currently in use.

Halozyme shares rose 11 cents, or 6.2 percent, to $1.88 in afternoon trading on the American Stock Exchange, and shares of Baxter fell 1 cent to $39.58 on the New York Stock Exchange.

Last Trade: 2.09
Trade Time: 3:41PM ET
Change: Up 0.32 (18.08%)
Prev Close: 1.77
Open: 1.87
Bid: N/A
Ask: N/A
1y Target Est: 3.94

Gruß Cyberhai